CN113552340A - Drug detection test strip and drug detection kit - Google Patents
Drug detection test strip and drug detection kit Download PDFInfo
- Publication number
- CN113552340A CN113552340A CN202110652322.4A CN202110652322A CN113552340A CN 113552340 A CN113552340 A CN 113552340A CN 202110652322 A CN202110652322 A CN 202110652322A CN 113552340 A CN113552340 A CN 113552340A
- Authority
- CN
- China
- Prior art keywords
- detection
- drug
- pad
- test strip
- membrane
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/558—Immunoassay; Biospecific binding assay; Materials therefor using diffusion or migration of antigen or antibody
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5308—Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/577—Immunoassay; Biospecific binding assay; Materials therefor involving monoclonal antibodies binding reaction mechanisms characterised by the use of monoclonal antibodies; monoclonal antibodies per se are classified with their corresponding antigens
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/582—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with fluorescent label
Abstract
The invention relates to a drug detection test strip and a drug detection kit. The drug detection test strip comprises: the detection device comprises a sample pad, a combination pad, a detection membrane, an absorption pad and a bottom plate, wherein the sample pad, the combination pad, the detection membrane and the absorption pad are sequentially connected on the bottom plate; the combination pad is provided with at least one drug luminescent microsphere labeled specific monoclonal antibody, the detection membrane is provided with at least one detection line respectively corresponding to drugs, the detection lines are coated with corresponding drug synthetic antigens, and the drugs comprise at least one of hemp, ecstasy and cocaine or a composition thereof. The drug detection test strip can be used for simultaneously detecting three common drugs in hair, is convenient to obtain materials, stable to store, high in sensitivity and good in specificity, can effectively improve the detection efficiency of law enforcement officers, and reduces the detection cost.
Description
Technical Field
The invention relates to the technical field of drug detection, in particular to a test strip, a kit and a preparation method for detecting hemp, ecstasy and cocaine in hair by using a time-resolved fluorescence immunochromatography method.
Background
For more than twenty years, the hair drug analysis technology is rapidly developed, and body fluid (mainly urine and blood) is still a better biological detection material for detecting drugs, but the detection time limit of the drugs in the body fluid is short, after a drug addict absorbs the drugs, the components and the content of the drugs are difficult to accurately detect through the urine, the blood and saliva due to metabolism within 3 to 7 days generally, the detection material is difficult to store, and the drug addict information of the examinee in a longer period of time cannot be explored, so that part of drug addicts evade the investigation and management. In the traditional hair detection technology, the time for obtaining the result by the high performance liquid chromatography is long, the operation is complex, and the method is not suitable for field law enforcement work.
Disclosure of Invention
Therefore, it is necessary to provide a drug test strip, a drug kit and a preparation method thereof, which can rapidly detect drugs, have high sensitivity and good specificity, in order to solve the problems of short detection time, long detection time and complicated operation.
A drug detection drug test strip, said drug detection test strip comprising: the detection device comprises a sample pad, a combination pad, a detection membrane, an absorption pad and a bottom plate, wherein the sample pad, the combination pad, the detection membrane and the absorption pad are sequentially connected on the bottom plate; the combination pad is provided with at least one drug luminescent microsphere labeled specific monoclonal antibody, the detection membrane is provided with at least one detection line respectively corresponding to drugs, the detection lines are coated with corresponding drug synthetic antigens, and the drugs comprise at least one of hemp, ecstasy and cocaine or a composition thereof.
In one embodiment, the conjugate pad of the drug test strip has at least one specific monoclonal antibody labeled with a luminescent microsphere, and the detection membrane of the drug test strip has at least one detection line.
In one embodiment, the test strip for testing drugs is prepared by the following steps: marking a synthetic antigen solution of at least one drug on the detection membrane to form detection lines corresponding to different drugs; at least one of the drugs marijuana, ecstasy and cocaine; and drying to obtain the detection membrane.
In one embodiment, the conjugate pad is prepared by the following steps: and uniformly coating at least one specific monoclonal antibody solution of the drug marked by the luminous microspheres on the bonding pad, and drying to obtain the drug.
In one embodiment, the synthetic antigen solution is obtained by diluting the corresponding synthetic antigen to a concentration of 0.3-1 mg/mL using a phosphate buffer or trehalose diluent.
In one embodiment, the detection membrane is further provided with a quality control line coated with the goat anti-chicken IgY antibody.
The drug detection test strip in one embodiment further comprises the steps of marking on the detection membrane by using a goat anti-chicken IgY antibody solution, and drying to form a quality control line; the goat anti-chicken IgY antibody solution is obtained by diluting a goat anti-chicken IgY antibody to a concentration of 1-3 mg/mL by using a phosphate buffer solution or a trehalose diluent.
In one embodiment, the luminescent microspheres are time-resolved fluorescent microspheres.
In one embodiment, the preparation method of the drug-specific monoclonal antibody solution labeled by the luminescent microspheres comprises the following steps:
dissolving the luminescent microspheres in MES buffer solution, and adding EDC/NHS activator for activation;
after the activation, washing and centrifugation, redissolving the luminescent microspheres by using boric acid buffer solution, and then adding monoclonal antibodies of corresponding drugs for reaction;
adding a sealing agent for sealing after the reaction is finished;
and after blocking, washing and centrifuging, collecting the solid, re-dissolving the solid by using a boric acid buffer solution and a blocking agent, and performing ultrasonic treatment to uniformly disperse the specific monoclonal antibody marked by the luminescent microspheres in the buffer solution.
In one embodiment, the mass ratio of the luminescent microspheres to the specific monoclonal antibody is (0.8-1.2 mg) to 0.1 mg; and/or
The blocking agent is bovine serum albumin; and/or
The concentration of the specific monoclonal antibody marked by the luminescent microspheres in the specific monoclonal antibody solution of the drug marked by the luminescent microspheres is 0.1-1 mg/mL.
A drug detection kit comprising: a detection card, a sample lysate and the drug detection test strip according to any one item;
the detection card is provided with a detection cavity, a sample adding slot and an observation window which are communicated with the detection cavity, at least one drug detection test strip is arranged in the detection cavity, and the drugs used for detection by the at least one drug detection test strip are not repeated; the detection line is exposed to the observation window, the sample pad is positioned in the sample adding slot of the detection card, and the detection line is exposed to the observation window of the detection card.
According to the drug detection test strip, the time-resolved luminescent microspheres are adopted for marking and matching with the preferred antibody antigen, so that the high sensitivity requirement of detecting the cannabis, the ecstasy and the cocaine drugs in the hair is met. And three common drugs in the hair can be detected simultaneously, so that the convenience of detecting the drugs in the hair is greatly improved.
The drug detection kit adopts the unique sample lysate, can quickly release the hemp, the ecstasy and the cocaine in the hair, does not influence the specificity and the sensitivity of detection, can be stably stored at room temperature for a long time, is convenient to obtain materials and stable to store, and brings great convenience for detection. After the sample lysate used in the method is added with hair ultrasonic waves, the sample lysate can be added with sample to detect cannabis, ecstasy and cocaine narcotics in the hair, and can also be added with other hair narcotic series reagent cards, so that the method has wide application range and flexible operation.
In addition, the time for detecting three corresponding drugs by using the drug detection kit is 10min, which is about ten times faster than the time required by the traditional detection method, so that the detection efficiency is greatly improved, the detection cost is reduced, and the requirement of field law enforcement in field detection is met.
Experiments prove that the hemp sensitivity can reach 2.0ng/mL, the ecstasy pill sensitivity can reach 1.0ng/mL and the cocaine sensitivity can reach 5.0ng/mL by using the hair hemp, ecstasy pill and cocaine drug detection test strip manufactured by the method. Obviously superior to the sensitivity of products corresponding to the common rapid drug detection in the market. 30 negative samples are detected by the method, 30 hair samples with standard hemp, ecstasy and cocaine as positive samples are respectively detected, and the detection coincidence rate is 100%.
Drawings
Fig. 1 is a schematic structural diagram of a drug test strip according to an embodiment of the present invention.
Wherein, the corresponding relation between the reference signs and the component names is as follows:
1. a sample pad; 2. a bonding pad; 3. a detection membrane; 4. an absorbent pad; 5. a base plate; 6. a quality control line; 7. and detecting lines.
Detailed Description
To facilitate an understanding of the invention, the invention will now be described more fully with reference to the accompanying drawings. The preferred embodiments of the present invention are illustrated in the accompanying drawings. This invention may, however, be embodied in many different forms and should not be construed as limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete.
It will be understood that when an element is referred to as being "secured to" or "disposed" on another element, it can be directly on the other element or intervening elements may also be present. When an element is referred to as being "connected" to another element, it can be directly connected to the other element or intervening elements may also be present.
Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. The terminology used in the description of the invention herein is for the purpose of describing particular embodiments only and is not intended to be limiting of the invention. As used herein, the term "and/or" includes any and all combinations of one or more of the associated listed items.
As shown in fig. 1, an embodiment of the present invention provides a drug test strip, which includes a sample pad 1, a conjugate pad 2, a detection membrane 3, an absorption pad 4 and a bottom plate 5, wherein the sample pad 1, the conjugate pad 2, the detection membrane 3 and the absorption pad 4 are connected in sequence on the bottom plate 5; the combination pad 2 is provided with at least one specific monoclonal antibody (such as monoclonal antibody product produced by soliloving biotechnology limited, Guangzhou) marked by luminescent microsphere of drug, the detection membrane 3 is provided with at least one detection line 7 respectively corresponding to the drug, the detection line 7 is coated with corresponding synthetic antigen of the drug (such as synthetic antigen produced by soliloving biotechnology limited, Guangzhou), and the drug comprises at least one of hemp, ecstasy and cocaine or a combination thereof.
In this embodiment, the binding pad 2 is provided with at least one drug-labeled specific monoclonal antibody labeled with the luminescent microspheres, which can be specifically bound with the detected drug small molecules with high efficiency. The detection membrane 3 in this example is a nitrocellulose membrane. The detection membrane 3 is provided with at least one detection line 7 corresponding to the corresponding drugs respectively. Each detection line 7 is coated with a corresponding drug synthetic antigen, a small molecule coupled with bovine serum albumin, a substance similar to the detection drug molecule, and is more favorable for being combined on the detection membrane 3. The drugs to be detected are respectively marijuana (THC), ecstasy (MDMA) and cocaine (COC).
The drug detection test strip adopts the luminescent microspheres as the markers, when the drug antigen molecules in the sample to be detected are combined with the drug specific monoclonal antibody marked by the luminescent microspheres in the combination pad 2 and are subjected to forward chromatography through capillary action, and when the drug antigen molecules reach the detection area, the drug antigen molecules are combined with the drug antibody fixed on the detection line to form a sandwich compound of the luminescent microspheres, the drug specific monoclonal antibody, the drug antigen and the drug antibody, and the sandwich compound is fixed on the detection line. After the reaction is finished, the detection area is scanned and detected by exciting light, the detection line emits light, and the decay time is longer. By delaying the measurement time and measuring the specific light after all spontaneous background light in the sample to be measured decays, the interference of background light can be eliminated, and the detection sensitivity of the sample to be measured is greatly improved.
In this embodiment, a specific monoclonal antibody labeled with a luminescent microsphere is disposed on the binding pad 2 of the drug test strip, and a detection line is disposed on the detection membrane 3 of the drug test strip. At the moment, the drug detection test strip has good detection specificity and high accuracy.
In the specific example shown in fig. 1, three specific monoclonal antibodies labeled with luminescent microspheres are disposed on the binding pad 2 of each drug test strip, and three detection lines are disposed on the detection membrane 3 of the drug test strip. Therefore, the drug test strip can realize the function of simultaneously testing three drugs. Greatly improving the efficiency of drug detection.
In the drug test strip of the embodiment, the preparation steps of the detection membrane are as follows: and coating the specific monoclonal antibody solution marked by the luminous microspheres on a detection membrane. Marking the synthetic antigen solution of at least one drug on a detection membrane to form detection lines corresponding to different drugs; the drug is at least one of marijuana, ecstasy and cocaine, and is obtained after drying. The drying condition for preparing the detection membrane can be, but is not limited to, drying at 37-45 ℃ for 12-48 hours.
In the drug test strip of this embodiment, the conjugate pad is prepared by the following steps: and uniformly coating at least one specific monoclonal antibody solution of the drug marked by the luminous microspheres on the bonding pad, and drying to obtain the drug. The drying condition for producing the bonding pad may be, but is not limited to, drying at 37-45 ℃ for 1-7 hours.
In one embodiment, the synthetic antigen solution is obtained by diluting the corresponding synthetic antigen to a concentration of 0.3mg/mL to 1mg/mL using a phosphate buffer solution with a concentration of preferably 0.005 to 0.02mol/L and a pH value of 7.2 to 7.4 or a trehalose diluent with a concentration of 0.05% to 4% and a pH value of 7.2 to 7.4.
As shown in FIG. 1, in the drug test strip of the present embodiment, the detection membrane 3 is further provided with a quality control line 6, and the quality control line 6 is preferably coated with anti-goat IgY antibody. By arranging the quality control line 6 on the detection membrane 3, drug antigen molecules in a sample to be detected are combined with the drug specific monoclonal antibody marked by the luminescent microspheres in the combination pad 2 and are subjected to forward chromatography through capillary action, and after reaching a detection area, the drug antigen molecules are combined with the drug antibody fixed on the detection line 7 to form a sandwich compound of the luminescent microspheres, the drug specific monoclonal antibody, the drug antigen and the drug antibody and are fixed on the detection line, and redundant luminescent microsphere markers are continuously subjected to forward chromatography and are combined with a secondary antibody fixed on the quality control line 6. After the reaction is finished, the detection area is scanned and detected by exciting light, the detection line emits light, and the decay time is longer. And (3) after all background light spontaneously generated in the sample to be detected decays by using the delayed measurement time, measuring specific light, and analyzing the concentration of the drug to be detected in the sample to be detected by using the ratio of the luminous intensity of the detection line 7 to the luminous intensity of the quality control line 6.
Further, the drug test strip in this embodiment further includes a step of marking on the detection membrane 3 with a goat anti-chicken IgY antibody solution, and drying to form a quality control line 6. The goat anti-chicken IgY antibody solution is preferably obtained by diluting a goat anti-chicken IgY antibody to a concentration of 1-3 mg/mL by using a phosphate buffer solution with a concentration of 0.005-0.02 mol/L, a pH value of 7.2-7.4 or a trehalose diluent with a concentration of 0.05-4% and a pH value of 7.2-7.4.
In the drug detection test strip in the embodiment, the luminescent microspheres are time-resolved fluorescent microspheres, the specific monoclonal antibody of the drug to be detected, such as a rare earth element fluorescent marker, is marked by using a marker with long decay life, the specific monoclonal antibody is marked by using a rare earth element, fluorescence is measured by using a time-resolved technology according to the luminescent characteristics of a rare earth element chelate, and meanwhile, two parameters of wavelength and time are detected for signal resolution, so that the interference of non-specific fluorescence is effectively eliminated, and the analysis sensitivity is greatly improved.
In the drug test strip of this embodiment, the drug-specific monoclonal antibody solution labeled with the luminescent microsphere is prepared by the following steps:
dissolving luminescent microspheres (such as fluorescent microspheres) with the wavelength of 200-400 nm produced by Dongguan Hannuo biotechnology limited in MES buffer solution with the pH of 20-100 mM preferably being 5-7, adding EDC/NHS activator for room temperature activation, preferably adding 5-50 mu L, and keeping the time for 10-60 min;
washing and centrifuging after activation, re-dissolving the collected luminescent microspheres with boric acid buffer solution, preferably with the concentration of 5-50 mM and the pH of 7-8.5, and then adding specific monoclonal antibodies of corresponding drugs for reaction;
after the reaction is finished, adding a sealing agent for sealing, wherein the preferred addition amount is 50-100 mu L;
and after blocking, washing and centrifuging, collecting the solid, redissolving the solid by using a boric acid buffer solution and a blocking agent, preferably adding the boric acid buffer solution and the blocking agent with the concentration of 5 mM-20 mM and the pH value of 7-8.5, adding the volume of the recovered specific monoclonal antibody, uniformly dispersing the specific monoclonal antibody marked by the luminescent microspheres in the buffer solution by ultrasonic treatment, and storing the specific monoclonal antibody at the temperature of 2-8 ℃ in a dark place.
The mass ratio of the luminescent microspheres to the specific monoclonal antibody is preferably (0.8-1.2) to 0.3, and the blocking agent is preferably bovine serum albumin. The concentration of the specific monoclonal antibody marked by the luminescent microspheres in the finally prepared specific monoclonal antibody solution of the three drugs marked by the luminescent microspheres is preferably 0.1 mg/mL-1 mg/mL.
The corresponding solution can be sprayed uniformly onto the pre-treated conjugate pad using, but not limited to, a BioDot dot blotter. The pretreatment is to add 0.05 to 2.50 percent of Tween-80 or 10 to 80mL of TX-100 solution into the combined pad for drying and modification.
The invention also provides a drug detection kit, which comprises: a detection card, a sample lysate and a drug detection test strip as any one of the above items;
the detection card is provided with a detection cavity, a sample adding slot and an observation window which are communicated with the detection cavity, at least one drug detection test strip is arranged in the detection cavity, and the drugs used for detection by the at least one drug detection test strip are not repeated; the detection line is exposed in the observation window, the sample pad is positioned in the sample adding slot of the detection card, and the detection line is exposed in the observation window of the detection card. Preferably, the sample lysate in the drug detection kit is a liquid which can rapidly crack hair and release hemp (THC), ecstasy (MDMA) and cocaine (COC), and is dispensed into 2mL frozen storage tubes for storage.
The following is a specific test example section.
And cutting a small amount of root hair of a suspect during detection, cutting into pieces, putting the cut hair into hair lysate, carrying out ultrasonic treatment for 5 minutes, sucking the hair lysate, adding the hair lysate into a sample port of a detection card, waiting for 5 minutes, putting the hair lysate into a fluorescence quantitative analyzer, reading data, and finally respectively obtaining the contents of hemp (THC), dancing outreach (MDMA) and cocaine (COC) in the hair.
The detection time of the detection reagent strip for the hair hemp (THC), the dancing outreach (MDMA) and the cocaine (COC) prepared by the method is 10min, which is about tens of times faster than that of the traditional detection method (hours).
After hair is added into the hair lysate used by the method for ultrasonic detection, the drugs such as marijuana (THC), anabola (MDMA) and cocaine (COC) in the hair can be added and detected, and the drugs can also be added into other hair drug series reagent cards, so that the detection efficiency and the detection convenience are greatly improved.
According to the hair hemp (THC), ecstasy (MDMA) and cocaine (COC) reagent cards prepared by the method, the sensitivity of The Hemp (THC) can reach 2.0ng/mL, the sensitivity of the ecstasy (MDMA) can reach 1.0ng/mL, and the sensitivity of the cocaine (COC) can reach 5.0 ng/mL. Obviously superior to the sensitivity of products corresponding to the common rapid drug detection in the market.
30 negative samples are detected by the method, 30 hair samples with standard hemp (THC), ecstasy (MDMA) and cocaine (COC) as positive samples are added, and the detection coincidence rate is 100%.
The technical features of the embodiments described above may be arbitrarily combined, and for the sake of brevity, all possible combinations of the technical features in the embodiments described above are not described, but should be considered as being within the scope of the present specification as long as there is no contradiction between the combinations of the technical features.
The above-mentioned embodiments only express several embodiments of the present invention, and the description thereof is more specific and detailed, but not construed as limiting the scope of the invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention. Therefore, the protection scope of the present patent shall be subject to the appended claims.
Claims (10)
1. A drug detection test strip, said drug detection test strip comprising: the detection device comprises a sample pad (1), a combination pad (2), a detection membrane (3), an absorption pad (4) and a bottom plate (5), wherein the sample pad (1), the combination pad (2), the detection membrane (3) and the absorption pad (4) are sequentially connected on the bottom plate (5); the combination pad (2) is provided with at least one drug specific monoclonal antibody marked by luminescent microspheres, the detection membrane (3) is provided with at least one detection line (7) respectively corresponding to drugs, the detection line (7) is coated with corresponding drug synthetic antigens, and the drugs comprise at least one of hemp, ecstasy and cocaine or a composition thereof.
2. The drug detection strip according to claim 1, wherein the binding pad (2) of the drug detection strip has at least one specific monoclonal antibody labeled with a luminescent microsphere, and the detection membrane (3) of the drug detection strip has at least one detection line (7).
3. The drug detection strip according to claim 1, wherein the detection membrane (3) is prepared by the steps of: marking a synthetic antigen solution of at least one drug on the detection membrane (3) to form detection lines (7) corresponding to different drugs; the drug is at least one of marijuana, ecstasy and cocaine; drying to obtain the detection membrane (3); and/or
The preparation steps of the combined pad (2) are as follows: and (3) uniformly coating the solution of at least one specific monoclonal antibody of the drug marked by the luminous microspheres on the binding pad (2), and drying to obtain the drug.
4. The drug test strip of claim 3, wherein the synthetic antigen solution is obtained by diluting the corresponding synthetic antigen to a concentration of 0.3-1 mg/mL using phosphate buffer or trehalose diluent.
5. The drug detection strip of claim 1, wherein the detection membrane (3) is further provided with a quality control line coated with anti-goat IgY antibody.
6. The drug detection strip of claim 5, further comprising a step of streaking using a goat anti-chicken IgY antibody solution on the detection membrane (3) and drying to form a quality control line (6); the solution of the anti-chicken IgY antibody is obtained by diluting the anti-chicken IgY antibody to the concentration of 1-3 mg/mL by using a phosphate buffer solution or a trehalose diluent.
7. The drug detection strip of claim 1, wherein the luminescent microspheres are time-resolved fluorescent microspheres.
8. The drug detection strip of claim 1, wherein the luminescent microsphere labeled drug-specific monoclonal antibody solution is prepared by the following steps:
dissolving the luminescent microspheres in MES buffer solution, and adding EDC/NHS activator for activation; after the activation, washing and centrifugation, redissolving the luminescent microspheres by using boric acid buffer solution, and then adding monoclonal antibodies of corresponding drugs for reaction;
adding a sealing agent for sealing after the reaction is finished;
and after blocking, washing and centrifuging, collecting the solid, re-dissolving the solid by using a boric acid buffer solution and a blocking agent, and performing ultrasonic treatment to uniformly disperse the specific monoclonal antibody marked by the luminescent microspheres in the buffer solution.
9. The drug detection strip of claim 8, wherein the mass ratio of the luminescent microspheres to the specific monoclonal antibody is (0.8-1.2 mg):0.1 mg; and/or
The blocking agent is bovine serum albumin; and/or
The concentration of the specific monoclonal antibody marked by the luminescent microspheres in the specific monoclonal antibody solution of the drug marked by the luminescent microspheres is 0.1-1 mg/mL.
10. A drug detection kit, comprising: a test card, a sample lysate and the drug test strip according to claims 1-9 above;
the detection card is provided with a detection cavity, a sample adding slot and an observation window which are communicated with the detection cavity, at least one drug detection test strip is arranged in the detection cavity, and the drugs used for detection by the at least one drug detection test strip are not repeated; the detection line is exposed to the observation window, the sample pad (1) is positioned in the sample adding slot of the detection card, and the detection line is exposed to the observation window of the detection card.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110652322.4A CN113552340A (en) | 2021-06-11 | 2021-06-11 | Drug detection test strip and drug detection kit |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110652322.4A CN113552340A (en) | 2021-06-11 | 2021-06-11 | Drug detection test strip and drug detection kit |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113552340A true CN113552340A (en) | 2021-10-26 |
Family
ID=78130539
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110652322.4A Pending CN113552340A (en) | 2021-06-11 | 2021-06-11 | Drug detection test strip and drug detection kit |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113552340A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114660249A (en) * | 2021-12-31 | 2022-06-24 | 江苏致准检测技术服务有限公司 | Domestic sewage component detection method capable of realizing accurate tracing and equipment thereof |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110850095A (en) * | 2019-11-22 | 2020-02-28 | 佛山墨赛生物技术有限公司 | Drug trace detection test strip and preparation method and kit thereof |
-
2021
- 2021-06-11 CN CN202110652322.4A patent/CN113552340A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110850095A (en) * | 2019-11-22 | 2020-02-28 | 佛山墨赛生物技术有限公司 | Drug trace detection test strip and preparation method and kit thereof |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114660249A (en) * | 2021-12-31 | 2022-06-24 | 江苏致准检测技术服务有限公司 | Domestic sewage component detection method capable of realizing accurate tracing and equipment thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106872420B (en) | Kit and method for time-resolved fluorescence quantitative detection of microalbuminuria | |
| CN102323422B (en) | Immunochromatographic test strip for semi-quantitatively and simultaneously detecting cTnI and Myo and preparation method thereof | |
| CN106153927A (en) | A kind of fast quantification detects time-resolved fluoroimmunoassay chromatography reagent and the preparation method of cTnI, CKMB, Myo simultaneously | |
| WO2018120855A1 (en) | Time-resolved fluorescent immunochromatographic test strip and kit for detecting myo, and preparation method therefor | |
| CN108398562A (en) | Cystatin C fluorescent micro-ball immune chromatography quantitative testing test paper item and test card | |
| CN108333357A (en) | A kind of magnetic bead time-resolved fluoroimmunoassay quantitatively detects CK-MB kits | |
| CN101339196A (en) | Rapid checking method for bladder cancer by quantum dot mark immunity-chromatography test paper | |
| CN110850095A (en) | Drug trace detection test strip and preparation method and kit thereof | |
| CN112362867A (en) | Detection method using aggregation-induced emission combined immunomagnetic beads and kit thereof | |
| CN110927395A (en) | Triple test strip for detecting methamphetamine, morphine and ketamine as well as preparation method and application method thereof | |
| CN113567666A (en) | Fluorescent microsphere labeled immunochromatography novel coronavirus detection test strip and preparation method and application thereof | |
| CN115436627A (en) | Cystatin C fluorescence immunochromatography detection kit and preparation method thereof | |
| CN113552340A (en) | Drug detection test strip and drug detection kit | |
| CN106645043A (en) | Kit and method for fast quantitatively detecting small molecule compound | |
| CN109633163B (en) | procalcitonin/C reactive protein two-in-one detection kit | |
| CN110927380A (en) | Duplex test strip for detecting methamphetamine and ketamine as well as preparation method and application method thereof | |
| CN205049578U (en) | Terminal brain sodium peptide (NT -proBNP) quantitative determination kit of N | |
| CN106645703A (en) | Kit and method for quickly and quantitatively detecting small-molecular compounds | |
| CN114167052A (en) | Kit for quantitative detection of NT-proBNP/ST2 by time-resolved fluorescence immunochromatography and application thereof | |
| US20220308049A1 (en) | Lateral flow test strips with competitive assay control | |
| CN113740543A (en) | Kit for rapidly detecting proportion of glycosylated hemoglobin and preparation method thereof | |
| CN116413445A (en) | Detection card, kit and detection method for detecting total thyroxine content | |
| CN113588960A (en) | Immunochromatography detection test strip by ratio fluorescence method and detection method thereof | |
| CN111879930A (en) | Creatine kinase isoenzyme MB detection kit and preparation method thereof | |
| CN117147885B (en) | Reagent for jointly determining multiple drugs in hair and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |